| Modulating ROS to overcome multidrug resistance in cancer Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta, L Wei, CR Ashby Jr, ... Drug Resistance Updates 41, 1-25, 2018 | 489 | 2018 |
| Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance S Narayanan, CY Cai, YG Assaraf, HQ Guo, Q Cui, L Wei, JJ Huang, ... Drug Resistance Updates 48, 100663, 2020 | 223 | 2020 |
| Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance JQ Wang, Y Yang, CY Cai, QX Teng, Q Cui, J Lin, YG Assaraf, ZS Chen Drug Resistance Updates 54, 100743, 2021 | 141 | 2021 |
| Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters YF Fan, W Zhang, L Zeng, ZN Lei, CY Cai, P Gupta, DH Yang, Q Cui, ... Cancer letters 421, 186-198, 2018 | 112 | 2018 |
| Targeting cancer cell mitochondria as a therapeutic approach: recent updates Q Cui, S Wen, P Huang Future Medicinal Chemistry 9 (9), 929-949, 2017 | 73 | 2017 |
| The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy Y Liu, H Sun, B Makabel, Q Cui, J Li, C Su, CR Ashby Jr, Z Chen, J Zhang Oncology reports 42 (1), 20-34, 2019 | 59 | 2019 |
| N‐Benzyldithiocarbamate Salts as Sulfur Sources to Access Tricyclic Thioheterocycles Mediated by Copper Species B Luo, Q Cui, H Luo, Y Hu, P Huang, S Wen Advanced Synthesis & Catalysis 358 (17), 2733-2738, 2016 | 50 | 2016 |
| Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells JQ Wang, JY Li, QX Teng, ZN Lei, N Ji, Q Cui, L Zeng, Y Pan, DH Yang, ... Cancers 12 (2), 466, 2020 | 44 | 2020 |
| Repositioning lidocaine as an anticancer drug: the role beyond anesthesia D Zhou, L Wang, Q Cui, R Iftikhar, Y Xia, P Xu Frontiers in Cell and Developmental Biology 8, 565, 2020 | 40 | 2020 |
| Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells W Feng, M Zhang, ZX Wu, JQ Wang, XD Dong, Y Yang, QX Teng, ... Frontiers in oncology 10, 955, 2020 | 38 | 2020 |
| Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible Q Cui, Y Yang, N Ji, JQ Wang, L Ren, DH Yang, ZS Chen Future Medicinal Chemistry 11 (4), 323-336, 2019 | 34 | 2019 |
| Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study N Ji, Y Yang, CY Cai, JQ Wang, ZN Lei, ZX Wu, Q Cui, DH Yang, ZS Chen, ... Frontiers in oncology 9, 514, 2019 | 32 | 2019 |
| A novel danshensu derivative prevents cardiac dysfunction and improves the chemotherapeutic efficacy of doxorubicin in breast cancer cells L Wang, X Zhang, JYW Chan, L Shan, G Cui, Q Cui, Y Wang, J Li, H Chen, ... Journal of Cellular Biochemistry 117 (1), 94-105, 2016 | 32 | 2016 |
| Design, synthesis, and preliminary cardioprotective effect evaluation of danshensu derivatives Q Cui, Y Chen, M Zhang, L Shan, Y Sun, P Yu, G Zhang, D Wang, Z Zhao, ... Chemical Biology & Drug Design 84 (3), 282-291, 2014 | 29 | 2014 |
| Glesatinib, a c-MET/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells Q Cui, CY Cai, HL Gao, L Ren, N Ji, P Gupta, S Shukla, SV Ambudkar, ... Frontiers in Oncology 9, 313, 2019 | 28 | 2019 |
| Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor Y Yang, N Ji, CY Cai, JQ Wang, ZN Lei, QX Teng, ZX Wu, Q Cui, Y Pan, ... Cancer Communications 40 (7), 285-300, 2020 | 27 | 2020 |
| Reversal of cancer multidrug resistance (MDR) mediated by ATP-binding cassette transporter G2 (ABCG2) by AZ-628, a RAF kinase inhibitor JQ Wang, QX Teng, ZN Lei, N Ji, Q Cui, H Fu, L Lin, DH Yang, YF Fan, ... Frontiers in Cell and Developmental Biology 8, 601400, 2020 | 24 | 2020 |
| Chk1 inhibitor MK-8776 restores the sensitivity of chemotherapeutics in P-glycoprotein overexpressing cancer cells Q Cui, CY Cai, JQ Wang, S Zhang, P Gupta, N Ji, Y Yang, X Dong, ... International Journal of Molecular Sciences 20 (17), 4095, 2019 | 22 | 2019 |
| Reversal effect of ALK inhibitor NVP-TAE684 on ABCG2-overexpressing cancer cells J Wang, JQ Wang, CY Cai, Q Cui, Y Yang, ZX Wu, X Dong, L Zeng, ... Frontiers in oncology 10, 228, 2020 | 21 | 2020 |
| NVP-CGM097, an HDM2 inhibitor, antagonizes ATP-binding cassette subfamily B member 1-mediated drug resistance M Zhang, XY Chen, XD Dong, JQ Wang, W Feng, QX Teng, Q Cui, J Li, ... Frontiers in oncology 10, 1219, 2020 | 19 | 2020 |
Zhe-Sheng ChenCollege of Pharmacy and Health Sciences, St. John's University在 stjohns.edu 的电子邮件经过验证
